Agenus (AGEN) Shares Down 5.4%
Agenus Inc (NASDAQ:AGEN) dropped 5.4% on Friday . The company traded as low as $2.79 and last traded at $2.82. Approximately 1,228,954 shares traded hands during mid-day trading, a decline of 32% from the average daily volume of 1,811,624 shares. The stock had previously closed at $2.98.
AGEN has been the subject of a number of recent research reports. Zacks Investment Research lowered shares of Agenus from a “hold” rating to a “sell” rating in a report on Tuesday, January 8th. BidaskClub upgraded shares of Agenus from a “hold” rating to a “buy” rating in a report on Thursday, January 10th. Finally, ValuEngine upgraded shares of Agenus from a “hold” rating to a “buy” rating in a report on Thursday, January 17th.
The firm has a market capitalization of $393.24 million, a price-to-earnings ratio of -1.96 and a beta of 2.09.
A number of large investors have recently bought and sold shares of AGEN. Northern Trust Corp raised its holdings in Agenus by 4.3% during the 2nd quarter. Northern Trust Corp now owns 1,005,499 shares of the biotechnology company’s stock valued at $2,282,000 after buying an additional 41,300 shares during the last quarter. Wells Fargo & Company MN raised its holdings in Agenus by 26.7% in the 3rd quarter. Wells Fargo & Company MN now owns 941,284 shares of the biotechnology company’s stock worth $2,015,000 after purchasing an additional 198,247 shares in the last quarter. BlackRock Inc. raised its holdings in Agenus by 3.1% in the 3rd quarter. BlackRock Inc. now owns 5,896,521 shares of the biotechnology company’s stock worth $12,619,000 after purchasing an additional 178,555 shares in the last quarter. Virtu Financial LLC bought a new position in Agenus in the 3rd quarter worth $105,000. Finally, Jefferies Group LLC raised its holdings in Agenus by 171.2% in the 3rd quarter. Jefferies Group LLC now owns 166,523 shares of the biotechnology company’s stock worth $356,000 after purchasing an additional 105,123 shares in the last quarter. Institutional investors own 31.76% of the company’s stock.
TRADEMARK VIOLATION WARNING: This story was published by Watch List News and is owned by of Watch List News. If you are reading this story on another domain, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The correct version of this story can be accessed at https://www.watchlistnews.com/agenus-agen-shares-down-5-4/2910719.html.
About Agenus (NASDAQ:AGEN)
Agenus Inc, a clinical-stage immuno-oncology company, focuses on the discovery and development of therapies that engage the body's immune system to fight cancer. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; SECANT yeast display, an antibody discovery platform used for the generation of novel monoclonal antibodies; and phage display technologies.
See Also: Why does a company issue an IPO?
Receive News & Ratings for Agenus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus and related companies with MarketBeat.com's FREE daily email newsletter.